BRPI1008977A2 - anticorpo para pcrv humanizado que possui atividade anti-pseudomonal - Google Patents

anticorpo para pcrv humanizado que possui atividade anti-pseudomonal

Info

Publication number
BRPI1008977A2
BRPI1008977A2 BRPI1008977A BRPI1008977A BRPI1008977A2 BR PI1008977 A2 BRPI1008977 A2 BR PI1008977A2 BR PI1008977 A BRPI1008977 A BR PI1008977A BR PI1008977 A BRPI1008977 A BR PI1008977A BR PI1008977 A2 BRPI1008977 A2 BR PI1008977A2
Authority
BR
Brazil
Prior art keywords
pcrv antibody
humanized
pseudomonal activity
pseudomonal
activity
Prior art date
Application number
BRPI1008977A
Other languages
English (en)
Inventor
Keiko Kawamoto
Takafumi Sato
Toshinaga Tsuji
Yoshito Numata
Yoshinori Yamano
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI1008977A2 publication Critical patent/BRPI1008977A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1008977A 2009-03-11 2010-03-09 anticorpo para pcrv humanizado que possui atividade anti-pseudomonal BRPI1008977A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009057929 2009-03-11
PCT/JP2010/053828 WO2010104052A1 (ja) 2009-03-11 2010-03-09 抗緑膿菌作用を有するヒト化ＰｃｒＶ抗体

Publications (1)

Publication Number Publication Date
BRPI1008977A2 true BRPI1008977A2 (pt) 2016-10-04

Family

ID=42728341

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008977A BRPI1008977A2 (pt) 2009-03-11 2010-03-09 anticorpo para pcrv humanizado que possui atividade anti-pseudomonal

Country Status (18)

Country Link
US (2) US20120093808A1 (pt)
EP (1) EP2407537B3 (pt)
JP (1) JP5780595B2 (pt)
KR (1) KR101686261B1 (pt)
CN (2) CN102341496B (pt)
AU (1) AU2010222150B2 (pt)
BR (1) BRPI1008977A2 (pt)
CA (1) CA2754900A1 (pt)
DK (1) DK2407537T6 (pt)
EA (1) EA021101B1 (pt)
ES (1) ES2529734T7 (pt)
IL (1) IL214959A (pt)
MX (1) MX2011009100A (pt)
PL (1) PL2407537T6 (pt)
PT (1) PT2407537E (pt)
SG (2) SG174225A1 (pt)
TW (1) TWI489995B (pt)
WO (1) WO2010104052A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020544B1 (ru) * 2008-01-10 2014-12-30 Шионоги Энд Ко., Лтд. АНТИТЕЛА ПРОТИВ PcrV
SG174225A1 (en) 2009-03-11 2011-10-28 Shionogi & Co Humanized pcrv antibody having anti-pseudomonal activity
HRP20201370T1 (hr) * 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
CA2925897A1 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
EP3983015A1 (en) * 2019-06-11 2022-04-20 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
MY208387A (en) 2019-07-09 2025-05-05 Beijing Solobio Genetechnology Co Ltd Antibodies specifically recognizing pseudomonas pcrv and uses thereof
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
AU2024307442A1 (en) 2023-06-28 2026-02-19 Universität Zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1666058B1 (en) 1998-11-25 2011-12-28 MCW Research Foundation, Incorporated Method of diagnosing a Pseudomonas aeruginosa infection
US20030228324A1 (en) 1999-05-06 2003-12-11 Malcolm Andrew J. Peptide compositions and methods of producing and using same
WO2002064161A2 (en) 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
WO2005066970A2 (en) 2003-12-30 2005-07-21 Sandisk Corporation Robust data duplication and improved update method in a multibit non-volatile memory
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
CN101454446A (zh) 2006-03-30 2009-06-10 明治制果株式会社 绿脓杆菌的外膜蛋白pa0427
WO2009005040A1 (ja) 2007-06-29 2009-01-08 Meiji Seika Kaisha Ltd. 緑膿菌の外膜タンパク質pa4710
BRPI0819598A2 (pt) * 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
EA020544B1 (ru) * 2008-01-10 2014-12-30 Шионоги Энд Ко., Лтд. АНТИТЕЛА ПРОТИВ PcrV
SG174225A1 (en) 2009-03-11 2011-10-28 Shionogi & Co Humanized pcrv antibody having anti-pseudomonal activity

Also Published As

Publication number Publication date
KR20110128856A (ko) 2011-11-30
US9085611B2 (en) 2015-07-21
KR101686261B1 (ko) 2016-12-14
AU2010222150B2 (en) 2015-07-16
WO2010104052A1 (ja) 2010-09-16
SG174225A1 (en) 2011-10-28
ES2529734T3 (es) 2015-02-25
IL214959A (en) 2016-04-21
TWI489995B (zh) 2015-07-01
EP2407537A4 (en) 2012-12-26
CA2754900A1 (en) 2010-09-16
MX2011009100A (es) 2011-09-27
CN104119437A (zh) 2014-10-29
EP2407537B1 (en) 2014-11-26
PL2407537T6 (pl) 2016-07-29
PL2407537T3 (pl) 2015-04-30
AU2010222150A1 (en) 2011-09-08
CN102341496A (zh) 2012-02-01
PT2407537E (pt) 2015-02-17
US20120093808A1 (en) 2012-04-19
DK2407537T3 (en) 2015-02-09
ES2529734T7 (es) 2015-08-11
EA201190163A1 (ru) 2013-01-30
US20130108627A1 (en) 2013-05-02
JP5780595B2 (ja) 2015-09-16
EP2407537B3 (en) 2015-05-20
CN102341496B (zh) 2014-07-02
SG10201400520WA (en) 2014-05-29
JPWO2010104052A1 (ja) 2012-09-13
TW201032825A (en) 2010-09-16
EP2407537A1 (en) 2012-01-18
DK2407537T6 (en) 2015-07-27
IL214959A0 (en) 2011-11-30
EA021101B1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
LTPA2019011I1 (lt) CGRP antikūnai
IL257822A (en) Mice that make heavy chain antibodies
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
EP2482848A4 (en) Endoglin antibodies
BR112012030311A2 (pt) anticorpo
PT2530091T (pt) Anticorpo anti-dll3
BRPI1008977A2 (pt) anticorpo para pcrv humanizado que possui atividade anti-pseudomonal
DK2521736T3 (da) Humaniserede antistoffer
DK3842456T3 (da) Monoklonalt Interleukin-31-antistof
EP2629796A4 (en) ANTIBODY
CO6811812A2 (es) Anticuerpo anti-b7-h3
EP2473531A4 (en) Anti-gitr antibodies
BR112014010198A2 (pt) Anticorpos humanizados que reconhecem alfa- sinucleína
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
DK3336225T3 (da) Antistofbiblioteker
SMT201600193B (it) Nuovo anticorpo anti-dr5
PT2853545T (pt) Anticorpo específico para ige
CR20140127A (es) Anticuerpo anti-abtcr
PT2569013T (pt) Anticorpos monoclonais humanizados e quiméricos para cd47
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
DK2651436T3 (da) Mycobakterie antigen sammensætning.
SMT201700083B (it) Anticorpi monoclonali
CO6791565A2 (es) Anticuerpos anti-notch1
DOP2011000313A (es) Anticuerpos especificos para caderin-17

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]